HMB Enriched Amino Acids to Reverse Muscle Loss in Cirrhosis

Status Recruiting

Clinical Trial Summary

Loss of skeletal muscle mass or sarcopenia is the most common and potentially reversible complication in cirrhosis that increases morbidity and mortality before, during and after liver transplantation. No proven treatments exist for the prevention or reversal of sarcopenia in cirrhosis, primarily because the mechanisms responsible for this are unknown. Based on compelling preliminary studies and those of the co investigator, investigators hypothesize that the mechanism of reduced skeletal muscle mass in cirrhosis is due to a myostatin mediated impaired mTOR (mechanistic target of rapamycin) signaling resulting in reduced protein synthesis and increased autophagy. Investigators further postulate that leucine, a direct stimulant of mTOR, will reverse the impaired mTOR phosphorylation in the skeletal muscle of cirrhotics. The consequent increase in protein synthesis reduced autophagy will result in an increase in skeletal muscle mass. Investigators will test these hypotheses by quantifying the response to acute and long term (3 month) administration of hydroxymethyl butyrate (HMB) enriched essential amino acid compared with an isonitrogenous isocaloric non-essential balanced amino acid mixture (does not stimulate protein synthesis) in cirrhotic patients. Fractional protein synthesis rate (FSR) in skeletal muscle, responses of the molecular regulatory pathways of skeletal muscle protein synthesis, and autophagy flux will be quantified in the acute and long term protocols. Tracer studies using L-[D5]-phenylalanine (Phe) as a primed constant infusion (prime 2µmol.kg-1.hr-1; constant 0.05 µmol.kg-1.hr-1) with and L [ring-D2] tyrosine, forearm plethysmography, and sequential skeletal muscle biopsies (total of 3 per study subject) will be used to quantify these outcomes. Anthropometric, clinical and body composition measures will be additional outcome measures for the long term intervention. Expression of regulatory signaling proteins, myostatin, IGF-1 (insulin like growth factor) , phospho-Akt, phospho-AMPK (activated protein kinase), phospho-mTOR and phospho-p70s6k will be quantified by Western immunoblots. Autophagy flux will be measured by quantifying expression of the autophagosome proteins.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05166499
Study type	Interventional
Source	The Cleveland Clinic
Contact	Annette Bellar
Phone	2164456268
Email	bellara@ccf.org
Status	Recruiting
Phase	N/A
Start date	November 30, 2021
Completion date	December 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05793983` - S100A8/A9 and Innate Immunity in Liver Disease
Completed	`NCT04604860` - Use of EL-FIT App to Promote Physical Activity	N/A
Recruiting	`NCT05928624` - A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients	N/A
Active, not recruiting	`NCT01438970` - Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function	Phase 2
Recruiting	`NCT05998330` - LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease	N/A
Completed	`NCT04581369` - Cirrhosis Medical Home	N/A
Withdrawn	`NCT04244877` - Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility	Phase 3
Recruiting	`NCT04588077` - Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis	Phase 4
Recruiting	`NCT05538962` - Longitudinal Monitoring of Inflammation in Cirrhosis	N/A
Completed	`NCT04082780` - Rifamycin in Minimal Hepatic Encephalopathy	Phase 2
Completed	`NCT03850977` - Is There an Association Between Chronic Pancreatitis and Pulmonary Function
Active, not recruiting	`NCT03736265` - Carvedilol for Prevention of Esophageal Varices Progression	N/A
Recruiting	`NCT04530760` - Intraabdominal Hypertension and Occurrence of Microaspiration in Cirrhotics Under Mechanical Ventilation
Recruiting	`NCT05093218` - Effect of Branch Chain Amino Acid Therapy on Sarcopenia in Children With Chronic Liver Disease.	N/A
Recruiting	`NCT03437876` - Study on Effect of Intestinal Microbiota Transplantation in Hepatitis B Virus Induced Cirrhosis	N/A
Recruiting	`NCT05604274` - Longitudinal Monitoring of Stool Characteristics
Recruiting	`NCT04867954` - Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
Completed	`NCT04643795` - Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects	Phase 1
Active, not recruiting	`NCT02344680` - Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Completed	`NCT04121520` - Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.